产品介绍
Product Description
Motavizumab (MEDI-524, NUMAX, NISTmAb) is a second generation monoclonal antibody (mAb) derived from palivizumab (Synagis) using affinity maturation techniques. Motavizumab is currently undergoing US Food and Drug Administration review as a treatment for respiratory syncytial virus (RSV) prophylaxis. It has been evaluated in large-scale clinical studies, and has demonstrated efficacy in reducing the disease burden of RSV in high-risk infant populations.Motavizumab (MEDI-524, NUMAX, NISTmAb) has higher affinity and a longer half-life, was effective in reducing RSV hospitalization in high-risk full-term infants in the US, but was not licensed due to safety concerns (allergic reactions) .
技术参数
Specifications
| Host species | Humanized |
| Isotype | IgG1, kappa |
| Species reactivity | HRSV-A |
| Form | Liquid |
| Storage buffer | 0.01M PBS, pH 7.4. |
| Purity | >95% as determined by SDS-PAGE. |
| Clonality | Monoclonal |
| Applications | Research Grade Biosimilar |
| Target | F, Fusion glycoprotein F0, Fusion glycoprotein F2, p27, Intervening segment, Pep27, Peptide 27, Fusion glycoprotein F1 |
| Purification | Protein A/G purified from cell culture supernatant. |
| Endotoxin level | Please contact with the lab for this information. |
| Expression system | Mammalian Cells |
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. |
| Alternative Names | MEDI-524,NUMAX, NISTmAb, CR9503, CAS: 677010-34-3 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
